论文部分内容阅读
苯扎贝特(Benzafibrate),又名必降脂、必利片(Bezalip),属于较新的氯苯乙酸类似物,其化学组成为2-[4[2-(4-氯苯甲酰胺基)-乙基]苯氧基]-2-甲基-丙酸。该药最早由德国开发,八十年代初在英国首先上市,是一种治疗各型脂质代谢障碍(饮食疗法可治愈的Ⅰ型高脂血症除外)比较理想的药物。苯扎贝特的作用与氯苯丁酯(Clofibrate)基本相同,但作用较强。能使升高了的甘油三酯和胆固醇以及运载它们的低密度脂蛋白的水平明显降低。从而使高脂血症的脂质正常化。其作用机理可能是它一方面抑制HMGCoA(β-羟基-β-甲基戊二酰辅酶A)还原酶的合成以及该酶和底物的亲和力,从而减少胆固醇的合成;另一方面又通过增加脂蛋白脂酶
Benzafibrate, also known as Betalipid, Bezalip, belongs to a newer class of chlorophenylacetic acid and has a chemical composition of 2- [4 [2- (4-chlorobenzamido ) -ethyl] phenoxy] -2-methyl-propionic acid. The drug was first developed in Germany and was first marketed in the UK in the early 1980s. It is an ideal drug for the treatment of various types of lipid metabolism disorders (except type I hyperlipidemia that can be cured by diet therapy). Bezafibrate has the same effect as Clofibrate, but has a strong effect. Significantly lower levels of elevated triglycerides and cholesterol, as well as LDLs carrying them. Thus normalizing the lipid of hyperlipidemia. Its mechanism of action may be that it inhibits the synthesis of HMGCoA (β-hydroxy-β-methylglutaryl coenzyme A) reductase and the affinity of the enzyme and substrate, thereby reducing cholesterol synthesis; on the other hand, Lipoprotein lipase